We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Denies Broad Aduhelm Payments, But Expands Paths to Coverage
CMS Denies Broad Aduhelm Payments, But Expands Paths to Coverage
Alzheimer’s disease drug Aduhelm and other investigational anti-amyloid antibodies similar to Aduhelm will only be covered by Medicare and Medicaid if they’re used in the setting of a federally approved study, the Centers for Medicare and Medicaid Services (CMS) announced yesterday.